|Articles|January 11, 2023
- Pharmaceutical Executive: January 2023
- Volume 43
- Issue 01
What We Foresee in ’23: Pharm Exec’s Annual Industry Outlook
Exploring the most relevant topics affecting the biopharma industry as the new year gets underway—ranging from trends ripe with risk and opportunity to those driving more definitive growth opportunities in patient care.
Advertisement
Articles in this issue
over 3 years ago
Key Factors Attributing to a Successful Product Launchover 3 years ago
Closing the Digital Gap: FDA’s Oversight of Social Mediaover 3 years ago
Sales-Rep Compensation: Adding Long-Term Incentives to Mixover 3 years ago
Co-creating New Innovationsover 3 years ago
The Potential Impact of the IRAover 3 years ago
Patient Hubs Continue Growthover 3 years ago
Social Media’s Complex Climbover 3 years ago
Industry Workforce Seeks Clarityover 3 years ago
Cybersecurity Threats & PharmaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Oral Weight Loss Pill Prescribed Over 1,000 Times in First Days on Market
2
The Turning Point for Oral Biologics: Q&A With Morten Graugaard
3
FDA’s Shift Signals a New Era for Data-Driven Drug Development
4
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request
5
